Over 480 000 cases of multidrug-resistant (MDR) tuberculosis (TB) occur every year
globally, 9% of them being affected by extensively drug-resistant (XDR) strains of …

Over recent years, tuberculosis (TB) and disease caused by human immunodeficiency virus
(HIV) have merged in a synergistic pandemic. The number of new cases of TB is stabilizing …

Summary According to the World Health Organization (WHO), 10.4 million people died of
tuberculosis (TB) in 2015, and the disease is now the number one cause of death from a …

Application of clinical pharmacology best practices is essential to the efficient and rational
development of drugs. In general, knowledge gained about exposure–response …

Modern tuberculosis (TB) chemotherapy is widely viewed as a crowning triumph of anti-
infectives research. However, only one new TB drug has entered clinical practice in the past …

Background Tuberculosis (TB) is a global health challenge and one of the leading causes of
death worldwide. In the last decade, the TB treatment landscape has dramatically changed …

Tuberculosis (TB) drug development has made substantial progress in the past decade.
There are currently at least ten drugs being evaluated in clinical trials. Some belong to …

With an estimated 1.7 million deaths attributed to it each year, tuberculosis (TB) is the single
leading infectious cause of death in the world. Combined chemotherapy has been the …

Introduction: The treatment of tuberculosis (TB) is a mature discipline, with more than 60
years of clinical experience accrued across the globe. The requisite Multi-drug treatment of …

Tuberculosis (TB) is a leading cause of morbidity and mortality worldwide, accounting for
about 9.6 million new cases and 1.5 million deaths annually. The poorest and socially …